戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              VATS excisional biopsy altered cytopathologic diagnosis
2                                              VATS lobectomy was associated with shorter length of sta
3 core matching resulted in 1464 open and 1464 VATS patients who were well matched by 14 common prognos
4 w-up of 7114 lobectomies (5566 open and 1548 VATS) was 52.0 months.
5             Materials and Methods Among 1950 VATS procedures performed in a single tertiary instituti
6 y score-matched analysis of 334 open and 334 VATS patients who were well matched by 14 common prognos
7 ow-up of 1559 lobectomies (1204 open and 355 VATS) was 43.2 months.
8  underwent lobectomy (thoracotomy, n = 8439; VATS, n = 4531) and met inclusion criteria.
9 published studies evaluating the impact of a VATS approach to lobectomy for N1 NSCLC on short-term ou
10 al rate after SABR was lower than that after VATS L-MLND by 12% or less and the upper bound of the 95
11                                          All VATS procedures represent an indication for OLV.
12                   In this national analysis, VATS lobectomy was used in the minority of N1 NSCLC case
13                   In this national analysis, VATS lobectomy was used in the minority of patients with
14 dule found at CT, microcoil localization and VATS resection were performed for a total of 126 nodules
15 llowing CT-guided microcoil localization and VATS.
16 ts undergoing lobectomy with thoracotomy and VATS, respectively (P < 0.0001).
17 l outcome between intrapleural urokinase and VATS for the treatment of childhood empyema.
18        A single pulmonary nodule resected at VATS was more likely to be malignant in patients with kn
19  than 1 cm but smaller than 3 cm resected at VATS were more likely to be malignant.
20  In 254 patients with one nodule resected at VATS, the nodules were malignant in 108 patients with an
21 eduction in mortality among GBV-C coinfected VATS subjects, after adjusting for HAART status, HIV RNA
22 , or a surgical opinion with regard to early VATS.
23 ncer (NSCLC) using a standard definition for VATS lobectomy (one 4- to 8-cm access and two 0.5-cm por
24 .7%, P = 0.76; multivariable-adjusted HR for VATS approach: 1.08, 95% CI: 0.90-1.30, P = 0.39).
25 of thoracic surgical patients presenting for VATS.
26 cted NSCLC were prospectively registered for VATS lobectomy.
27 m national studies on long-term survival for VATS versus open lobectomy are limited.
28                       Pathology reports from VATS performed between January 1995 and July 1997 were s
29 y after intervention between the two groups: VATS (median [range], 6 [3-16] d) versus urokinase (6 [4
30    Physical examination revealed well-healed VATS scars in the chest wall.
31                             Minimal invasive VATS is gaining widespread popularity among our surgical
32   Overall survival in the propensity-matched VATS L-MLND cohort was 91% (95% CI 85-98) at 3 years and
33 e-institution series demonstrated benefit of VATS lobectomy over lobectomy via thoracotomy in poor pu
34 are still lacking documenting the benefit of VATS versus conventional 'thoracotomy'.
35 ed to elucidate the technical feasibility of VATS in early non-small-cell lung cancer (NSCLC) using a
36 ggest the need for broader implementation of VATS techniques.
37 undergone lobectomy by either thoracotomy or VATS between 2000 and 2010.
38 drain with intrapleural urokinase or primary VATS.
39 scopic vision in the experimental group (PVB-VATS).
40 SD) of 48-hour opioid consumption in the PVB-VATS group (33.9 [19.8] mg; 95% CI, 30.0-37.9 mg) was no
41 signed to intervention groups: 98 in the PVB-VATS group (mean [SD] age, 64.6 [9.5] years; 53 female [
42 nce was demonstrated in total hospital stay: VATS versus urokinase (8 [4-17] d and 7 [4-25] d) (p = 0
43 titute's Viral Activation Transfusion Study (VATS), a randomized controlled trial of leukoreduced vs
44 ) of these 111 patients underwent successful VATS lobectomies.
45 , nor for video assisted thoracic surgeries (VATS) versus open transthoracic resections (67% vs 55%,
46 d safety of video-assisted thoracic surgery (VATS) lobectomy for small lung cancers.
47 omy or video-assisted thoracoscopic surgery (VATS) anatomic resection.
48 ough a video-assisted thoracoscopic surgery (VATS) approach.
49 erwent video-assisted thoracoscopic surgery (VATS) for right upper lobectomy.
50 rimary video-assisted thoracoscopic surgery (VATS) for the treatment of childhood empyema.
51 hether video-assisted thoracoscopic surgery (VATS) lobectomy is beneficial in high-risk pulmonary pat
52 use of video-assisted thoracoscopic surgery (VATS) or intrapleural enzyme therapy (IET) in pleural in
53 ulti-institutional studies that suggest that VATS does not compromise oncologic outcomes when used fo
54                                          The VATS approach was associated with a better 5-year surviv
55                                          The VATS approach was associated with a shorter median hospi
56                                          The VATS approach was not significantly different compared w
57  were no significant differences between the VATS and open approach with regard to nodal upstaging (1
58 y mortality, and 5-year survival between the VATS and open groups.
59  were significantly lower than those for the VATS arm US dollars 11,379 (US dollars 10,146) (p < 0.00
60 ne serious adverse event was reported in the VATS arm.
61 tween GBV-C coinfection and mortality in the VATS cohort.
62 was randomly matched with one patient in the VATS L-MLND group using a 5:1 digit greedy match algorit
63 SABR was not lower than that observed in the VATS L-MLND group.
64         After propensity score matching, the VATS approach was associated with a shorter median lengt
65 re cosmetic and economical advantages to the VATS approach, large randomized controlled trials are st
66 ents underwent video-assisted thoracoscopic (VATS) lobectomy and measurement of post-operative FEV1 a
67 -term survival of open versus thoracoscopic (VATS) lobectomy for early stage non-small-cell lung canc
68 re similar with video-assisted thoracoscopy (VATS) compared with thoracotomy.
69                   A standardized approach to VATS lobectomy as specifically defined with avoidance of
70 -term survival after SABR is non-inferior to VATS L-MLND for operable stage IA NSCLC.
71 rred, none of which were directly related to VATS technique; seven (7.4%) of 95 patients had grade 3
72 ts with clinical stage I NSCLC who underwent VATS L-MLND during the period of enrolment in this trial
73 tcomes of patients who underwent open versus VATS lobectomy for clinical T1-2, N0, M0 NSCLC in the Na
74 more economic treatment option compared with VATS and should be the primary treatment of choice.
75 d pulmonary complications when compared with VATS patients (P = 0.023).
76                                Compared with VATS, IET demonstrated a larger improvement in mean Euro
77 ary function after thoracotomy compared with VATS.